Yunnan Botanee Bio-Technology Group Co Ltd

Betaini's self-developed injectable sodium hyaluronate solution BTN001 has officially received approval from the National Medical Products Administration, obtaining a Class III medical device registration certificate with registration number 20263131919. This is the group's first self-developed Class III medical device approved for market. Institutional research reports note that Betaini, leveraging its Winona sensitive-skin base and Acoman clinical channel, uses BTN001 to close the loop of pre-operative stabilization, intra-operative injection, and post-operative repair, strengthening its full-cycle medical aesthetic service capability. The new product is restricted to medical institutions, with high barriers and large pricing space, and is expected to open a second growth curve. In terms of shareholder returns, as of August 31, 2026, the company had cumulatively repurchased 3.6997 million shares, accounting for 0.8734% of total share capital, with a total transaction amount of approximately 120 million yuan. At the same time, it launched its first interim dividend, proposing a cash dividend of 1.50 yuan per 10 shares to all shareholders, with an estimated total payout of approximately 62.639 million yuan. Controlling shareholder Guo Zhenyu also pledged in April this year not to reduce his holdings within 12 months. In the first half of 2026, Betaini achieved operating revenue of 2.592 billion yuan, up 9.27% year-on-year, net profit attributable to the parent of 292 million yuan, up 18.30% year-on-year, and non-GAAP net profit attributable to the parent of 246 million yuan, a sharp increase of 34.85% year-on-year. Net cash flow from operating activities was 394 million yuan, up 13.53% year-on-year. Gross margin reached 74.62%, and the selling expense ratio fell 3.64 percentage points year-on-year to 50.53%. However, Betaini's share price has fallen about 15% cumulatively this year, hovering around 30 to 35 yuan from late June to late September. As of September 30, it closed at 32.70 yuan per share, with a latest total market value of approximately 13.8 billion yuan.

Botanee announced on the evening of September 11 that its wholly owned subsidiary, Shanghai Botanee Health Technology Co., Ltd., received the Medical Device Registration Certificate of the People's Republic of China from the National Medical Products Administration on September 10. The product is an injectable sodium hyaluronate solution. The announcement shows that the product is used in medical institutions for superficial injection into the facial dermis to temporarily improve adult skin dryness and dull complexion. The company stated that obtaining the medical device registration certificate further supplements its medical device product line in the skin health field, complements its existing functional skincare products and related businesses, enriches its product matrix, and helps further enhance its core competitiveness and comprehensive market expansion capabilities.

Betaini announced on September 2 that as of August 31, 2026, the company had repurchased a total of 3.7 million shares through centralized bidding, accounting for 0.8734% of total share capital, with a total transaction amount of 120 million yuan. The highest repurchase price was 34.67 yuan per share, and the lowest was 29.84 yuan per share. In the first half of 2026, Betaini achieved revenue of 2.592 billion yuan and net profit attributable to the parent of 292 million yuan.

Betaini released its 2026 interim report. First-half net profit attributable to the parent company was 292 million yuan, up 18.3% year on year. Operating revenue was 2.59 billion yuan, up 9.3% year on year. Net profit attributable to the parent after deducting non-recurring items was 246 million yuan, up 34.9% year on year. Net operating cash flow was 394 million yuan, up 13.5% year on year. Second-quarter operating revenue was 1.47 billion yuan, up 3.6% year on year, and net profit attributable to the parent was 226 million yuan, up 3.4% year on year. The company said growth in operating revenue and profitability exceeded the growth rates of national total retail sales of consumer goods and domestic retail sales of cosmetics above designated size over the same period, and operating revenue for some brands on emerging e-commerce platforms rose more than 45 percent year on year.

Betaini announced plans to distribute a cash dividend of 1.5 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 62.64 million yuan. In the first half of 2026, Betaini achieved revenue of 2.592 billion yuan and net profit attributable to the parent company of 292 million yuan.

Botanee announced that as of the disclosure date, the company has repurchased 3.34 million shares, accounting for 0.7876% of total share capital. The repurchase transaction price range was 29.84 yuan to 34.67 yuan per share, and the total repurchase funds paid amounted to 108 million yuan. In the first quarter of 2026, Botanee achieved revenue of 1.118 billion yuan and net profit attributable to the parent company of 65.97 million yuan.